Intralesional antimoniate for treatment of cutaneous leishmaniasis: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i9.46905Keywords:
Diffuse Cutaneous Leishmaniasis; Cutaneous Leishmaniasis; Leishmaniasis.Abstract
Introduction: Leishmaniasis is an endemic protozoan parasitic infection. Cutaneous leishmaniasis is the most prevalent subtype in Latin America. It is estimated that approximately 1 million new cases are diagnosed annually. The pathology is initially characterized by a papule at the site of the insect bite that grows until it forms an ulcerated lesion. Method: Literature review with searches in the Scielo and PubMed databases, inclusion and exclusion criteria were applied, resulting in 24 articles, all discussed here. Results and Discussion: First-line therapy consists of the use of systemic antimoniates; however, many patients present side effects to the treatment, requiring discontinuation of use. Thus, in search of a therapeutic alternative, the use of intralesional antimoniate has shown to have similar efficacy to systemic treatment, being indicated for patients with few lesions, with a size smaller than 3 cm in diameter. Studies indicate that the use of intralesional antimoniate has few or no adverse effects, leading to initial and definitive cure in more than 50% of patients. In addition to proven efficacy, studies indicate other advantages of intralesional applications, such as: lower doses of antimony, flexible therapeutic schedule and more spaced applications. Conclusion: Intralesional antimoniate therapy presents satisfactory results, with high cure rates and few adverse effects. Global medical protocols are recommended.
References
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M., & WHO Leishmaniasis Control Team (2012). Leishmaniasis worldwide and global estimates of its incidence. PloS one, 7(5), e35671. https://doi.org/10.1371/journal.pone.0035671
Brito, N. C., Rabello, A. & Cota, G. F. (2017). Eficácia da terapia de infiltração intralesional de antimoniato pentavalente para leishmaniose cutânea: Uma revisão sistemática. 12(9):e0184777. doi: 10.1371/journal.pone.0184777. PMID: 28926630; PMCID: PMC5604971.
de Oliveira Duque, M. C., Quintão Silva, J. J., Soares, P. A. O., Magalhães, R. S., Horta, A. Pá. A., Paes, L. R. B., Rosandiski Lyra, M., Pimentel, M. Eu. F., de Fátima Antonio, L., de Camargo Ferreira E Vasconcellos, É., Saheki, M. N., de Almeida Marzochi, M. C., Valete-Rosalino, C. M., & de Oliveira Schubach, A. (2019). Comparação entre a terapia antimoniosa de meglumina sistêmica e intralesional em uma unidade de atenção primária à saúde. Acta tropica, 193, 176–182. https://doi.org/10.1016/j.actatropica.2019.03.
Duque, M. C., Vasconcellos, É. C., Pimentel, M. I., Lyra, M. R., Pacheco, S. J., Marzochi, M. C., Rosalino, C. M., & Schubach, A. O. (2016). Padronização do tratamento de antimoniose de meglumina intralesional para leishmaniose cutânea. Revista da Sociedade Brasileira de Medicina Tropical, 49(6), 774–776. https://doi.org/10.1590/0037-8682-0213-2016
Eid Rodríguez, D., San Sebastian, M., & Pulkki-Brännström, A. M. (2019). "Barato e melhor": Economia de custos sociais e impacto orçamentário da mudança de antimonios pentavalentes sistêmicos para intralesionais como o tratamento de primeira linha para a leishmaniose cutânea na Bolívia. Doenças tropicais negligenciadas PLoS, 13(11), e0007788. https://doi.org/10.1371/journal.pntd.0007788
Eskandari, S. E., Khamesipour, A., Jaafari, M. R., Javadi, A., Mohammadi, A. M., Valian, H. K., Nassiri-Kashani, M., Goyonlo, V. M., & Firooz, A. (2021). Combinação de anfotericina lipossômica tópica B e Glucantime em comparação com glucantima isoladamente para o tratamento da leishmaniose cutânea antroponótica (LCA) causada por Leishmania tropica: protocolo de estudo para um ensaio randomizado e controlado. Jornal iraniano de microbiologia, 13(5), 718–723. https://doi.org/10.18502/ijm.v13i5.7440
Farajzadeh, S., Ahmadi, R., Mohammadi, S., Pardakhty, A., Khalili, M., & Aflatoonian, M. (2018) Avaliação da eficácia do Glucantime intralesional mais sulfato de zinco niossômico em comparação com Glucantime intralesional mais crioterapia no tratamento da leishmaniose cutânea aguda, um ensaio clínico randomizado. Jornal de doenças parasitárias: órgão oficial da Sociedade Indiana de Parasitologia, 42(4), 616–620. https://doi.org/10.1007/s12639-018-1044-5
Machado-Silva, A., Guimarães, P. P., Tavares, C. A., & Sinisterra, R. D. (2015). New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. Expert opinion on therapeutic patents, 25(3), 247–260. https://doi.org/10.1517/13543776.2014.993969
Mokhtari, F., Gholami, M., Siadat, A. H., Jafari-Koshki, T., Faghihi, G., Nilforoushzadeh, M. A., Hosseini, S. M., & Abtahi-Naeini, B. (2017). Efficacy of Intense-pulsed Light Therapy with Topical Benzoyl Peroxide 5% versus Benzoyl Peroxide 5% Alone in Mild-to-moderate Acne Vulgaris: A Randomized Controlled Trial. Journal of research in pharmacy practice, 6(4), 199–205. https://doi.org/10.4103/jrpp.JRPP_17_29
Okwa O. O. (2007). Tropical parasitic diseases and women. Annals of African medicine, 6(4), 157–163. https://doi.org/10.4103/1596-3519.55704
Oliveira, L. F., Schubach, A. O., Martins, M. M., Passos, S. L., Oliveira, R. V., Marzochi, M. C., & Andrade, C. A. (2011). Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta tropica, 118(2), 87–96. https://doi.org/10.1016/j.actatropica.2011.02.007
Omidian, M., Jadbabaei, M., Omidian, E., & Omidian, Z. (2019). O efeito da terapia a laser Nd:YAG na leishmaniose cutânea em comparação com o antimonio de meglumina intralesional. Dermatologia e alergias postes, 36(2), 227–231. https://doi.org/10.5114/ada.2019.82827
OPAS. (2021). Organização Pan-Americana da Saúde. Leishmaniose: Relatório Epidemiológico das Américas [Internet]. Nº 10 de dezembro de 2021.OPAS; Washington, DC, EUA. Disponível online: https://iris.paho.org/handle/10665.2/51742[Google Acadêmico]
OPAS. (2022). Organização Pan-Americana da Saúde. Diretriz para o Tratamento da Leishmaniose nas Américas. (2a ed.), OPAS; Washington, DC, EUA:
Palumbo E. (2010). Treatment strategies for mucocutaneous leishmaniasis. Journal of global infectious diseases, 2(2), 147–150. https://doi.org/10.4103/0974-777X.62879
Queiroz, R. & Feferbaum, M. (2022). Metodologia da pesquisa em direito. Saraiva.
Ramalho, D. B., Silva, R. E. D., Senna, M. C. R., Moreira e H. S. A., Pedras, M. J., Avelar, D. M., Saraiva, L., Rabello, A., & Cota, G. (2018). Infiltração intralesional antimoniada de meglumina para leishmaniose cutânea localizada: um ensaio clínico de fase II de braço único, de marca aberta. Memórias do Instituto Oswaldo Cruz, 113(9), e180200. https://doi.org/10.1590/0074-02760180200
Rojas Cabrera, E, Guzman-Rivero, M, Verduguez-Orellana, A, Córdova Rojas, M, Aranibar Aguilar, G, Campos, M A, & Campero Lino, E. (2022). Aplicación Intralesional de Antimoniales en el Tratamiento de Leishmaniasis Cutánea. Gaceta Médica Boliviana, 45(1), 6-11..https://doi.org/10.47993/gmb.v45i1.370
Siadat, A. H., Zolfaghari, A., Shahmoradi, Z., Shariat, S., & Sohrabi, K. (2020). Application of laser for treatment of cutaneous leishmaniasis: a review of literature. Lasers in medical science, 35(7), 1451–1457. https://doi.org/10.1007/s10103-020-03006-1
Siadat, A., Galehdari, H., Shahmoradi, Z., Iraji, F., Zolfaghari, A., & Ansari, N. (2023). Tratamento da Leishmaniose Cutânea com Luz Pulsada Intensa: É Eficaz?. Pesquisa biomédica avançada, 12, 125. https://doi.org/10.4103/abr.abr_410_21
Silva, R. E., Toledo, A., Júnior, Senna, M. C., Rabello, A., & Cota, G. (2016). Antimonioso de meglumina intralesional para o tratamento da leishmaniose cutânea localizada: uma revisão retrospectiva de um centro de referência brasileiro. Memórias do Instituto Oswaldo Cruz,111(8), 512–516. https://doi.org/10.1.590/0074-02760160183
Soto, J., Gutiérrez, P., Soto, P., Paz, D., Cayhuara, E., Molina, C., Sánchez, M., & Berman, J. (2022). Tratamento da Leishmania braziliensis Boliviana Leishmaniose Cutânea e Mucosa. A revista americana de medicina tropical e higiene, 106(4), 1182–1190. https://doi.org/10.4269/ajtmh.21-0928
Vasconcellos, E. C., Pimentel, M. I., Schubach, A. O., de Oliveira, R. V., Azeredo-Coutinho, R. B., Silva, F. C., Salgueiro, M. M., Moreira, J. S., Madeira, M. F., Baptista, C., & Valete-Rosalino, C. M. (2012). Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). The American journal of tropical medicine and hygiene, 87(2), 257–260. https://doi.org/10.4269/ajtmh.2012.11-0612
WHO. (2010). Control of the leishmaniases. World Health Organization technical report series, (949),
WHO. (2022). Leishmaniose da Organização Mundial da Saúde. Principais fatos. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
Yanik, M., Gurel, M. S., Simsek, Z., & Kati, M. (2004). The psychological impact of cutaneous leishmaniasis. Clinical and experimental dermatology, 29(5), 464–467. https://doi.org/10.1111/j.1365-2230.2004.01605.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aline Valério Barbosa Silveira; Rafaela Candido; Caroline Franciscato
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
